Cargando…

PB2417: PRESENCE´S IMPACT OF NON-SPECIFIC ANTI-HLA ANTIBODIES ON THE DEVELOPMENT OF PRIMARY GRAFT FAILURE IN PATIENTS UNDERGOING PERIPHERAL BLOOD HAPLOIDENTICAL HSCT, EXPERIENCE AT A CENTER IN MEXICO.

Detalles Bibliográficos
Autores principales:	Daniel Garza Escobar, Juan, Baltazar Arellano, Severiano, Sotomayor Duque, Guillermo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429113/ http://dx.doi.org/10.1097/01.HS9.0000976376.74417.06

Ejemplares similares

PB2462: IMPACT OF ENGRAFTMENT SYNDROME ON THE DEVELOPMENT OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC/HAPLOIDENTICAL PERIPHERAL BLOOD HSCT IN A SINGLE CENTER IN MEXICO.
por: Daniel Garza Escobar, Juan, et al.
Publicado: (2023)

PB2466: PERIPHERAL BLOOD AS GRAFT SOURCE FOR APLASTIC ANEMIA TRANSPLANT: OUTCOMES OF YOUNG ADULTS AND ADULTS IN A MEXICAN PUBLIC HOSPITAL
por: Sotomayor Duque, Guillermo, et al.
Publicado: (2023)

PB2190: HLA-HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER REDUCED-INTENSITY CONDITIONING
por: Kim, J., et al.
Publicado: (2022)

T‐cell depleted HLA‐haploidentical HSCT in a child with neuromyelitis optica
por: Ceglie, Giulia, et al.
Publicado: (2019)

PB2208: CAR-T TREATMENT POST FIRST ALLO-HSCT FAILURE MAY HAVE DIFFERENT PROCESSION COMPARING TO CAR-T BEFORE ALLO-HSCT
por: wang, D., et al.
Publicado: (2022)

PB2316: SAFETY AND EFFICACY OF AUTOLOGOUS HSCT IN NINE PATIENTS WITH AIDS-RELATED NON-HODGKIN LYMPHOMA
por: Liu, Jun, et al.
Publicado: (2023)

PB1940: ACQUIRED APLASTIC ANEMIA: THE CHALLENGE OF TREATMENT IN MEXICO. SINGLE HEMATOLOGY CENTER EXPERIENCE
por: Guajardo Leal, M. L., et al.
Publicado: (2022)

PB2260: CIDOFOVIR FOR THE TREATMENT OF ADENOVIRUS INFECTION IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): A SINGLE CENTER EXPERIENCE
por: Cacace, F., et al.
Publicado: (2022)

PB2450: SEX-ASSOCIATED OUTCOME DIFFERENCES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
por: Ussmann, Jule, et al.
Publicado: (2023)

PB2418: CLINICAL FEATURES AND PROGNOSIS OF ADENOVIRUS INFECTION AFTER HAPLOIDENTICAL DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Sun, Wei, et al.
Publicado: (2023)

PB2434: DONOR CELL INDUCING IMMUNE-TOLERANCE IMPROVED ENGRAFTMENT IN TΑΒ+ CELL DEPLETED HSCT IN PATIENTS WITH THALASSEMIA MAJOR
por: Liao, Jianyun, et al.
Publicado: (2023)

PB2441: CD34+ CELL DOSE EFFECTS ON CLINICAL OUTCOMES OF ALLO-HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)
por: Zhou, Shengnan, et al.
Publicado: (2023)

Impact of Donor-Specific anti-HLA Antibodies and Donor KIR Characteristics in Haploidentical HSCT for Beta-Thalassemia
por: Andreani, Marco, et al.
Publicado: (2017)

PB2411: THE EFFICACY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR AUTOLOGOUS-HSCT IN LOW-RISK AND INTERMEDIATE-RISK AML PATIENTS
por: Zhai, Weihua, et al.
Publicado: (2023)

PB2407: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) WITH CYCLOPHOSPHAMIDE IN PEDIATRIC HIGH-RISK ACUTE MYELOID LEUKEMIA (HR-AML)
por: Sun, Ming, et al.
Publicado: (2023)

PB2439: EARLIER ENGRAFTMENT WITHOUT INCREASE OF GVHD IN HIGHER DOSE OF CD34+ CELLS IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Tan, Tran-Der, et al.
Publicado: (2023)

PB2465: ALLOGENEIC HSCT OUTCOMES IN SIX PATIENTS WITH THERAPY RELATED MYELOID NEOPLASMS WITH A HISTORY OF OVARIAN CANCER TREATED WITH CHEMOTERAPY AND PARP INHIBITORS
por: Maria Edoardo Maraglino, Alessio, et al.
Publicado: (2023)

PB2189: HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH SEVERE CONGENITAL NEUTROPENIA:A CASE REPORT OF 13 YEARS OLD PATIENT
por: Wang, J., et al.
Publicado: (2022)

PB1771: THE SIGNIFICANCE OF MRD DETECTION BY FLOW CYTOMETRY IN TRACING R/R B-ALL PATIENTS RECEIVING CD-19-CART BRIDGING TO ALLO-HSCT
por: chen, M., et al.
Publicado: (2022)

PB2680: THE ACTOR-PARTNER INTERDEPENDENCE MEDIATION EFFECT OF INTIMATE RELATIONSHIP ON DYADIC COPING AND FEAR OF CANCER RECURRENCE IN PATIENTS AND THEIR SPOUSES WITH HEMATOLOGICAL MALIGNANCY AFTER HSCT
por: Zhang, Qiuhui, et al.
Publicado: (2023)

PB1769: REAL WORLD DATA OUTCOMES IN A SINGLE MEXICAN PUBLIC INSTITUTION. ADOLESCENTS AND YOUNG ADULTS (AYAS) WITH NEWLY DIAGNOSED OF ACUTE LYMPHOBLASTIC LEUKEMIA:COMPARATIVE RESULTS OF DIFFERENT PROTOCOLS
por: Sotomayor Duque, G., et al.
Publicado: (2022)

TCRαβ/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders
por: Merli, Pietro, et al.
Publicado: (2022)

PB2442: BLINATUMOMAB REDIRECTS DONOR LYMPHOCYTES AGAINST CD19+ ALL WITHOUT INCREASING THE RISK OF BYSTANDER ALLOREACTIVITY AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION
por: Mancusi, Antonella, et al.
Publicado: (2023)

PB1994: REAL WORLD DATA OF PATIENTS WITH MULTIPLE MYELOMA WITHOUT ACCESS A NOVEL AGENT IN FIRST LINE THERAPY IN PUBLIC HEALTH HOSPITAL IN MEXICO
por: Cruz, D., et al.
Publicado: (2022)

PB1752: ANALYSIS OF HLA-PEPTIDE BINDING POCKETS IN PATIENTS WITH ACUTE LEUKEMIA UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION
por: Boukouaci, W., et al.
Publicado: (2022)

Case report: HLA-haploidentical HSCT rescued with donor lymphocytes infusions in a patient with X-linked chronic granulomatous disease
por: Scheiermann, Julia, et al.
Publicado: (2023)

PB1866: IS ALLO-HSCT IN CR1 NECESSARY FOR AML PATIENTS WITH MRD NEGATIVITY ACHIEVED AFTER THE FIRST INDUCTION COURSE? RUSSIAN PROSPECTIVE MULTICENTER RANDOMIZED TRIAL IN AML PATIENTS UNDER THE AGE OF 60
por: Parovichnikova, Elena, et al.
Publicado: (2023)

PB2188: APPLICATION PROSPECT OF LOW DOSE PORCINE ANTITHYMOCYTE GLOBULIN IN HLA MATCHED SIBLING DONOR TRANSPLANTATION
por: chen, X., et al.
Publicado: (2022)

Deciphering the biology of KIR2DL3(+) T lymphocytes that are associated to relapse in haploidentical HSCT
por: David, Gaëlle, et al.
Publicado: (2021)

PB2455: THE DARK SIDE OF FECAL MICROBIOTA TRANSPLANTATION IN REFRACTORY ACUTE GASTROINTESTINAL GRAFT VERSUS HOST DISEASE.
por: Hari, Oumayma, et al.
Publicado: (2023)

PB2457: RUXOLITINIB AS TREATMENT IN PATIENTS WITH ACUTE AND CRONIC GRAFT-VERSUS-HOST DISEASE. REAL WORLD EVIDENCE
por: José Jiménez Nájar, Francisco, et al.
Publicado: (2023)

Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report
por: Baldo, Francesco, et al.
Publicado: (2021)

PB2287: END OF LIFE TRANSFUSIONS IN PATIENTS WITH AN ONCOLOGICAL DIAGNOSIS
por: Duque, L., et al.
Publicado: (2022)

Co-transplantation of mesenchymal stem cells makes haploidentical HSCT a potential comparable therapy with matched sibling donor HSCT for patients with severe aplastic anemia
por: Liu, Zenghui, et al.
Publicado: (2020)

PB2177: ANTITHYMOCYTE GLOBULIN AS TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE - 10 YEARS OF EXPERIENCE AT A SINGLE-CENTER
por: Dantas Rodrigues, C., et al.
Publicado: (2022)

Donor Specific Anti-HLA Antibody and Risk of Graft Failure in Haploidentical Stem Cell Transplantation
por: Kongtim, Piyanuch, et al.
Publicado: (2016)

PB1994: COMPARISON OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES WITH HIGH AND LOW OGATA SCORE VALUES ON CYTOMETRY IN RELATION TO THE PRESENCE OF CYTOGENETIC ABNORMALITIES - A PRELIMINARY STUDY
por: Gawronski, Krzysztof, et al.
Publicado: (2023)

PB2179: RETROSPECTIVE ANALYSIS OF THE EFFICACY AND SAFETY OF RUXOLITINIB IN CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD). A SINGLE-INSTITUTION EXPERIENCE.
por: Muñiz, Ó., et al.
Publicado: (2022)

PB2481: OUTCOMES OF INDIVIDUALS WITH CLONAL HEMATOPOIESIS EVALUATED AT A CANCER CENTER
por: Chien, Kelly, et al.
Publicado: (2023)

PB2344: RESILIENCE IN PATIENTS WITH LYMPHOID MALIGNANCIES: THE REPLY STUDY.
por: Dos Santos, G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cejnb9i0v1qoov361ss7354tid